Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Intramuscular Injections of Letrozole ISM at Different Strengths in Voluntary Healthy Post Menopausal Women (LISA-1)

Trial Profile

A Phase I, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Intramuscular Injections of Letrozole ISM at Different Strengths in Voluntary Healthy Post Menopausal Women (LISA-1)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Letrozole (Primary) ; Letrozole
  • Indications Breast cancer
  • Focus Pharmacokinetics
  • Acronyms LISA-1
  • Sponsors Rovi
  • Most Recent Events

    • 17 Jan 2019 Planned End Date changed from 1 Sep 2019 to 1 Jul 2020.
    • 17 Jan 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Jul 2020.
    • 22 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top